NCT01690598已完成1 期
Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown BRCA Status
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Phase I: Maximum tolerated dose, dose limiting toxicity and thus recommend phase II dose of veliparib
研究概览
简要总结
The purpose of this study is to investigate the effect of combined topotecan and veliparib (ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or unknown BRCA mutation status.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.
- •Verified progression by either RECIST criteria and/or GCIG CA125 criteria after previous first line chemotherapy or progression after later lines of cytotoxic treatment.
- •Platinum resistance or partially platinum sensitive disease
- •Relapsed within six months of prior first line/later lines of platinum-based therapy or
- •Relapsed within six-twelve months of prior first line/later lines of platinum-based therapy
- •Age ≥ 18 years.
- •Performance status 0-
- •Measurable disease by RECIST 1.1 or CA125 GCIG criteria
- •Adequate bone marrow function, liver function, renal function and coagulation parameters (within 7 days prior to enrollment):
- •WBC ≥ 3.0 x 10^9/l or neutrophils (ANC) ≥ 1.5 x 10^9/l
- •Platelet count ≥ 100 x 109/l
- •Hemoglobin ≥ 9.7 g/dl (6 mmol/L)
- •Serum bilirubin ≤ 1.5 x ULN
- •Serum transaminases ≤ 2.5 x ULN
- •Serum creatinine ≤ 1.5 x ULN
- •Written informed consent.
- •Tissue available for BRCAness analysis/BRCA mutation analysis.
排除标准
- •Prior treatment with a PARP inhibitor.
- •Patients with BRCA1/2 germline mutation.
- •Platinum-refractory disease (disease that progressed or was stable during prior platinum therapy)
- •Patients who have received (or are planning to receive) treatment with any other investigational agent, or who have participated in another clinical trial within 28 days prior to entering this trial.
- •Pregnant or breast-feeding. For fertile women a negative pregnancy test at screening is mandatory.
- •Fertile patients not willing to use acceptable and safe methods of contraception during and for 6 months after treatment
- •Other present or previous malignancy except curatively treated cervical cancer stage I, non-melanotic skin cancer or other cancer with minimal risk of relapse. Previous breast cancer is allowed, if disease free follow-up at least five years prior to enrollment.
- •CNS metastasis.
- •History of any chronic medical or psychiatric condition or laboratory abnormality, which is not medically controlled or in the opinion of the Investigator may increase the risks associated with study drug administration (e.g. diabetes, cardiac diseases, hypertension, renal or liver disease).
- •Allergy to the ingredients of the study medication.
研究组 & 干预措施
Veliparib and Topotecan
Experimental
干预措施: Veliparib (Drug)
Veliparib and Topotecan
Experimental
干预措施: Topotecan (Drug)
结局指标
主要结局
Phase I: Maximum tolerated dose, dose limiting toxicity and thus recommend phase II dose of veliparib
时间窗: 1 month
Phase II: To investigate response rates (based on either CA125 GCIG or RECIST criteria) of combination topotecan and veliparib (ABT888) in relapsed ovarian cancer with negative or unknown BRCA status
时间窗: Every three months, up to 3 years
次要结局
- Overall survival of ovarian cancer patients treated with topotecan and veliparib(Every three months, up to three years)
- Progression free survival of ovarian cancer patients treated with topotecan and veliparib(Every three months up to three years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Veliparib and topotecan for ovarian cancer patients who are resistant to platinum containing chemotherapy and have negative or unknown BRCA statusRelapsed epithelial, platinum resistant ovarian cancer with negative or unknown BRCA statusMedDRA version: 14.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001661-32-DKVejle Hospital, Dept. of Oncology
尚未招募
2 期
Oral Topotecan With Toripalimab for Patients With Endometrial CancerEndometrial CancerNCT06548763Fudan University30
已完成
2 期
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical CancerCervical CancerNCT00548418Washington University School of Medicine27
已完成
1 期
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung CancerSmall Cell Lung CancerNCT02289690AbbVie221
进行中（未招募）
1 期
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerMetastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUnresectable Solid NeoplasmNCT01012817National Cancer Institute (NCI)88